Yizhe Wang - Jan 20, 2023 Form 4 Insider Report for LianBio (LIAN)

Role
Chief Executive Officer, Director
Signature
By: /s/ Angela Chen, Attorney-in-Fact
Stock symbol
LIAN
Transactions as of
Jan 20, 2023
Transactions value $
$0
Form type
4
Date filed
1/24/2023, 03:08 PM
Previous filing
Oct 29, 2021
Next filing
Mar 31, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LIAN Stock Option (Right to Buy) Award $0 +1.29M $0.00 1.29M Jan 20, 2023 Ordinary Shares 1.29M $2.66 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares underlying the option will vest and become exercisable on January 20, 2024; the remainder shall vest and become exercisable in 36 equal monthly installments such that the option shall be fully vested on January 20, 2027, subject to the Reporting Person providing continuous service to the Issuer on each such date.